TET protein inhibitors: Potential and limitations.

Dioxygenases / antagonists & inhibitors
Cancer Inhibitor Mitochondria TET protein Therapy

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 25 04 2023
revised: 31 07 2023
accepted: 10 08 2023
medline: 18 9 2023
pubmed: 21 8 2023
entrez: 20 8 2023
Statut: ppublish

Résumé

TET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.

Identifiants

DOI: 10.1016/j.biopha.2023.115324 PMID: 37598475
pubmed: 37598475
pii: S0753-3322(23)01115-0
doi: 10.1016/j.biopha.2023.115324
pii:
doi:

Substances chimiques

Dioxygenases EC 1.13.11.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115324

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Robert Kaplánek has no conflict of interest. Zdeněk Kejík has no conflict of interest. Jan Hajduch has no conflict of interest. Kateřina Veselá and Kateřina Kučnirová has no conflict of interest. Markéta Skaličková and Anna Venhauerová has no conflict of interest. Božena Hosnedlová has no conflict of interest. Róbert Hromádka has no conflict of interest. Petr Dytrych has no conflict of interest. Petr Novotný has no conflict of interest. Nikita Abramenko has no conflict of interest. Veronika Antonyová has no conflict of interest. David Hoshovec have no conflict of interest. Petr Babula has no conflict of interest. Michal Masařík has no conflict of interest. Pavel Martásek has no conflict of interest. Milan Jakubek has no conflict of interest.

Auteurs

Robert Kaplánek (R)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Zdeněk Kejík (Z)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Jan Hajduch (J)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Kateřina Veselá (K)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Kateřina Kučnirová (K)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Markéta Skaličková (M)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Anna Venhauerová (A)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Božena Hosnedlová (B)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Róbert Hromádka (R)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Petr Dytrych (P)

1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, 121 08 Prague, Czech Republic.

Petr Novotný (P)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Nikita Abramenko (N)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

Veronika Antonyová (V)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.

David Hoskovec (D)

1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, 121 08 Prague, Czech Republic.

Petr Babula (P)

Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic.

Michal Masařík (M)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic.

Pavel Martásek (P)

Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic. Electronic address: pavel.martasek@lf1.cuni.cz.

Milan Jakubek (M)

BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic. Electronic address: milan.jakubek@lf1.cuni.cz.

Articles similaires

Targeting TET3 in macrophages provides a concept strategy for the treatment of endometriosis.

Hossein Hosseinirad, Md Saidur Rahman, Jae-Wook Jeong
1.00
Endometriosis Female Humans Animals Mice

Injured inflammatory environment overrides the TET2 shaped epigenetic landscape of pluripotent stem cell derived human neural stem cells.

Noriko Kamei, Kenneth Day, Wei Guo et al.
1.00
Dioxygenases Humans Epigenesis, Genetic DNA-Binding Proteins Neural Stem Cells

Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.

Linlin Wang, Mingkai Shu, Zhibo Zhang et al.
1.00
Humans Nucleophosmin Leukemia, Myeloid, Acute Male Middle Aged

Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis.

Abhay Singh, Nuria Mencia Trinchant, Rahul Mishra et al.
1.00
Humans Clonal Hematopoiesis Immune Checkpoint Inhibitors Male Female

Classifications MeSH

questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxygénases › Dioxygenases › TET protein inhibitors: Potential and limitations.